

# Chonlaphat Sukasem

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7197211/publications.pdf>

Version: 2024-02-01

138  
papers

2,938  
citations

201385

27  
h-index

243296

44  
g-index

140  
all docs

140  
docs citations

140  
times ranked

3105  
citing authors

#	ARTICLE	IF	CITATIONS
1	HLA Allele-“Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction. Annual Review of Pharmacology and Toxicology, 2022, 62, .	4.2	8
2	Effects of the <i>CYP2C19</i> LoF allele on major adverse cardiovascular events associated with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. Pharmacogenomics, 2022, 23, 207-220.	0.6	14
3	Effect of GSTA1 Variants on Busulfan-Based Conditioning Regimen Prior to Allogeneic Hematopoietic Stem-Cell Transplantation in Pediatric Asians. Pharmaceutics, 2022, 14, 401.	2.0	2
4	Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies. Frontiers in Pharmacology, 2022, 13, 835136.	1.6	17
5	Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia. Pharmacogenomics and Personalized Medicine, 2022, Volume 15, 119-130.	0.4	1
6	Evolution of HLA-B Pharmacogenomics and the Importance of PGx Data Integration in Health Care System: A 10 Years Retrospective Study in Thailand. Frontiers in Pharmacology, 2022, 13, 866903.	1.6	3
7	Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics. Frontiers in Pharmacology, 2022, 13, 832048.	1.6	17
8	Pharmacogenomics in clinical practice to prevent risperidone-induced hyperprolactinemia in autism spectrum disorder. Pharmacogenomics, 2022, 23, 493-503.	0.6	5
9	Association of <i>UGT1A1*6</i> , <i>UGT1A1*28</i> , or <i>ABCC2 c.3972C&gt;T</i> genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis. Clinical and Translational Science, 2022, 15, 1613-1633.	1.5	8
10	Associations between UGT1A1 and SLCO1B1 polymorphisms and susceptibility to neonatal hyperbilirubinemia in Thai population. BMC Pediatrics, 2022, 22, 243.	0.7	1
11	Associations of <i>HLA</i> genetic variants with carbamazepine-induced cutaneous adverse drug reactions: An updated meta-analysis. Clinical and Translational Science, 2022, 15, 1887-1905.	1.5	17
12	Risperidone plasma concentrations are associated with hyperprolactinemia in autism spectrum disorder children: The impact of CYP2D6 polymorphisms. Research in Autism Spectrum Disorders, 2022, 96, 102002.	0.8	1
13	Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians. Journal of Allergy and Clinical Immunology, 2021, 147, 1402-1412.	1.5	46
14	Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1-13.	0.4	5
15	A novel nested allele-specific PCR protocol for the detection of the HLA-A*33:03, a SCAR-associated allele, in Vietnamese people. Asian Pacific Journal of Allergy and Immunology, 2021, , .	0.2	0
16	A Novel Allele-Specific PCR Protocol for the Detection of the HLA-C*03:02 Allele, a Pharmacogenetic Marker, in Vietnamese Kinh People. The Application of Clinical Genetics, 2021, Volume 14, 27-35.	1.4	3
17	Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: A comparative study of 100 patients with bullous pemphigoid and diabetes mellitus. Journal of Dermatology, 2021, 48, 486-496.	0.6	12
18	Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone. Scientific Reports, 2021, 11, 4158.	1.6	12

#	ARTICLE	IF	CITATIONS
19	Effect of 5-HT <sub>2C</sub> receptor gene polymorphism (HTR2C ~ 759C/T) on metabolic adverse effects in Thai psychiatric patients treated with risperidone. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 806-813.	0.9	1
20	Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing HLA-B*13:01. <i>Frontiers in Immunology</i> , 2021, 12, 658593.	2.2	14
21	Genetic Determinants in HLA and Cytochrome P450 Genes in the Risk of Aromatic Antiepileptic-Induced Severe Cutaneous Adverse Reactions. <i>Journal of Personalized Medicine</i> , 2021, 11, 383.	1.1	8
22	HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients. <i>Frontiers in Immunology</i> , 2021, 12, 661135.	2.2	29
23	Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population. <i>Scientific Reports</i> , 2021, 11, 12343.	1.6	16
24	Spectrum of cutaneous adverse reactions to aromatic antiepileptic drugs and human leukocyte antigen genotypes in Thai patients and meta-analysis. <i>Pharmacogenomics Journal</i> , 2021, 21, 682-690.	0.9	15
25	Resolving discordant CYP2D6 genotyping results in Thai subjects: platform limitations and novel haplotypes. <i>Pharmacogenomics</i> , 2021, 22, 529-541.	0.6	10
26	Influence of SULT1A1*2 Polymorphism on Plasma Efavirenz Concentration in Thai HIV-1 Patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 915-926.	0.4	2
27	Simplified and Rapid Determination of Primaquine and 5,6-Orthoquinone Primaquine by UHPLC-MS/MS: Its Application to a Pharmacokinetic Study. <i>Molecules</i> , 2021, 26, 4357.	1.7	4
28	Association of HLA-B*51:01, HLA-B*55:01, CYP2C9*3, and Phenytoin-Induced Cutaneous Adverse Drug Reactions in the South Indian Tamil Population. <i>Journal of Personalized Medicine</i> , 2021, 11, 737.	1.1	6
29	Genotyping HLA alleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1049-1064.	1.5	16
30	Pharmacogenomics research and its clinical implementation in Thailand: Lessons learned from the resource-limited settings. <i>Drug Metabolism and Pharmacokinetics</i> , 2021, 39, 100399.	1.1	18
31	TPMT*3C as a Predictor of 6-Mercaptopurine-Induced Myelotoxicity in Thai Children with Acute Lymphoblastic Leukemia. <i>Journal of Personalized Medicine</i> , 2021, 11, 783.	1.1	5
32	Associations of the SREBF2 Gene and INSIG2 Polymorphisms with Obesity and Dyslipidemia in Thai Psychotic Disorder Patients Treated with Risperidone. <i>Journal of Personalized Medicine</i> , 2021, 11, 943.	1.1	3
33	HLA Class-II-Restricted CD8+ T Cells Contribute to the Promiscuous Immune Response in Dapsone-Hypersensitive Patients. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2412-2425.e2.	0.3	12
34	A Comprehensive Review of HLA and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine. <i>Pharmaceuticals</i> , 2021, 14, 1077.	1.7	27
35	Pharmacogenomics Factors Influencing the Effect of Risperidone on Prolactin Levels in Thai Pediatric Patients With Autism Spectrum Disorder. <i>Frontiers in Pharmacology</i> , 2021, 12, 743494.	1.6	4
36	The Role of In Vitro Detection of Drug-Specific Mediator-Releasing Cells to Diagnose Different Phenotypes of Severe Cutaneous Adverse Reactions. <i>Allergy, Asthma and Immunology Research</i> , 2021, 13, 896.	1.1	8

#	ARTICLE	IF	CITATIONS
37	Patient, Disease, and Drug-Related Risk Factors Associated with Phenytoin-Induced Cutaneous Adverse Drug Reactions in South Indian Epileptic Patients.. <i>Current Drug Safety</i> , 2021, 16, .	0.3	4
38	Meta-Analysis of NUDT15 Genetic Polymorphism on Thiopurine-Induced Myelosuppression in Asian Populations. <i>Frontiers in Pharmacology</i> , 2021, 12, 784712.	1.6	5
39	Risperidone-Induced Obesity in Children and Adolescents With Autism Spectrum Disorder: Genetic and Clinical Risk Factors. <i>Frontiers in Pharmacology</i> , 2020, 11, 565074.	1.6	10
40	Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. <i>Scientific Reports</i> , 2020, 10, 13486.	1.6	18
41	Impact of <i>CYP2C19</i> , <i>CYP3A4</i> , <i>ABCB1</i> , and <i>FMO3</i> genotypes on plasma voriconazole in Thai patients with invasive fungal infections. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00665.	1.1	14
42	&lt;p&gt;CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia&lt;/p&gt;. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 543-551.	0.4	3
43	<i>NUDT15</i> genetic variants are related to thiopurine-induced neutropenia in Thai children with acute lymphoblastic leukemia. <i>Pharmacogenomics</i> , 2020, 21, 403-410.	0.6	15
44	Genetic Association of Co-trimoxazole-Induced Severe Cutaneous Adverse Reactions Is Phenotype-Specific: HLA Class I Genotypes and Haplotypes. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1078-1089.	2.3	34
45	Genetic Variations and Frequencies of the Two Functional Single Nucleotide Polymorphisms of <i>SLCO1B1</i> in the Thai Population. <i>Frontiers in Pharmacology</i> , 2020, 11, 728.	1.6	12
46	Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics. <i>Frontiers in Pharmacology</i> , 2020, 11, 78.	1.6	38
47	SJS/TEN 2019: From science to translation. <i>Journal of Dermatological Science</i> , 2020, 98, 2-12.	1.0	41
48	Genetic and clinical risk factors associated with phenytoin-induced cutaneous adverse drug reactions in Thai population. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 565-574.	0.9	23
49	<p>Pharmacogene Variation in Thai <i>Plasmodium vivax</i> Relapse Patients Treated with a Combination of Primaquine and Chloroquine</p> . <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 1-12.	0.4	7
50	Analysis of HLA-B Allelic Variation and IFN- $\gamma$ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 219-227.e4.	2.0	36
51	<p>Association between polymorphisms of <i>LEP</i>, <i>LEPR</i>, <i>DRD2</i>, <i>HTR2A</i> and <i>HTR2C</i> genes and risperidone- or clozapine-induced hyperglycemia</p> . <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 155-166.	0.4	6
52	Southeast Asian Pharmacogenomics Research Network (SEAPharm): Current Status and Perspectives. <i>Public Health Genomics</i> , 2019, 22, 132-139.	0.6	25
53	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2B6</i> and Efavirenz-Containing Antiretroviral Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 726-733.	2.3	125
54	Reliability and validity of the Thai Drug Hypersensitivity Quality of Life Questionnaire: a multi-center study. <i>International Journal for Quality in Health Care</i> , 2019, 31, 527-534.	0.9	8

#	ARTICLE	IF	CITATIONS
55	<sc>HLA</sc> Alleles and <i><sc>CYP</sc>2C9*3</i> as Predictors of Phenytoin Hypersensitivity in East Asians. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 476-485.	2.3	53
56	Drug-Induced Stevensâ€“Johnson Syndrome and Toxic Epidermal Necrolysis Call for Optimum Patient Stratification and Theranostics via Pharmacogenomics. <i>Annual Review of Genomics and Human Genetics</i> , 2018, 19, 329-353.	2.5	29
57	A LC/MS/MS method for determination of tenofovir in human plasma and its application to toxicity monitoring. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1085, 89-95.	1.2	10
58	Genetic polymorphisms of <i>HTR2C</i>, <i>LEP</i> and <i>LEPR</i> on metabolic syndromes in patients treated with atypical antipsychotic drugs. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 70, 536-542.	1.2	13
59	Pharmacogenetics of Risperidoneâ€“Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 42-50.	1.2	25
60	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>HLA</i> Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 574-581.	2.3	211
61	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 38-69.	2.0	134
62	Determination of plasma Levetiracetam level by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS) and its application in pharmacokinetics studies in neonates. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1085, 13-20.	1.2	3
63	Determination of irinotecan, <sc>SN</sc>â€“3 and <sc>SN</sc>â€“8 glucuronide using <sc>HPLC</sc>/<sc>MS</sc>: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, .	0.9	13
64	Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients. <i>Journal of Immunology Research</i> , 2018, 2018, 1-11.	0.9	55
65	UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder. <i>Pharmacogenomics Journal</i> , 2018, 18, 740-748.	0.9	14
66	Whole-Exome Sequencing Identifies One De Novo Variant in the <i>FGD6</i> Gene in a Thai Family with Autism Spectrum Disorder. <i>International Journal of Genomics</i> , 2018, 2018, 1-7.	0.8	3
67	<i>CYP2D6</i> genotype analysis of a Thai population: platform comparison. <i>Pharmacogenomics</i> , 2018, 19, 947-960.	0.6	16
68	Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 549-557.	1.0	16
69	Genotype - Phenotype correlations for Thiopurine Methyltransferase in Thai patients. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-14-30.	0.0	0
70	Pharmacogenomics: A New Approach for Preventing Severe Cutaneous Adverse Drug Reactions. , 2018, , 373-409.		2
71	The application of pharmacokinetics for Busulfan dose adjustment in hematopoietic stem cell transplantation (HSTC) in Thai children. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO1-11-3.	0.0	0
72	Correlation between voriconazole dosage regimen at steady state and <i>rs4646437</i> polymorphism. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-14-13.	0.0	0

#	ARTICLE	IF	CITATIONS
73	Clinical Pharmacogenomics and Personalized Medicine: New Strategies to Maximize Drug Efficacy and Avoid Adverse Drug Reaction. , 2018, , 239-261.		0
74	Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 185-191.	0.7	28
75	Development and Validation of Voriconazole Concentration by LC-MS/MS: Applied in Clinical Implementation. Journal of Clinical Laboratory Analysis, 2017, 31, .	0.9	14
76	Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders. Clinical Biochemistry, 2017, 50, 678-685.	0.8	30
77	Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions. European Journal of Clinical Pharmacology, 2017, 73, 855-865.	0.8	58
78	Pharmacogenomics and Efficacy of Risperidone Long-Term Treatment in Thai Autistic Children and Adolescents. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 316-324.	1.2	26
79	HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis. Scientific Reports, 2017, 7, 45553.	1.6	46
80	Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology, 2017, 88, 78-86.	1.5	117
81	Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population. Pharmacogenetics and Genomics, 2017, 27, 255-263.	0.7	25
82	Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients. Pharmacogenomics, 2017, 18, 1481-1490.	0.6	10
83	Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13. Pharmacogenetics and Genomics, 2017, 27, 429-437.	0.7	87
84	Development and validation of a reliable method for thiopurine methyltransferase (TPMT) enzyme activity in human whole blood by LC-MS/MS: An application for phenotypic and genotypic correlations. Journal of Pharmaceutical and Biomedical Analysis, 2017, 145, 758-764.	1.4	7
85	Molecular and immunological analyses of confirmed Plasmodium vivax relapse episodes. Malaria Journal, 2017, 16, 228.	0.8	8
86	Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population. Frontiers in Pharmacology, 2017, 8, 879.	1.6	44
87	Comparison between the HLA-B*15:01 Allele and 9 Single-Nucleotide Polymorphisms in Chromosome 6 for Prediction of Allopurinol-Induced Severe Cutaneous Adverse Reactions. Journal of Immunology Research, 2017, 2017, 1-9.		12
88	P2Y6 receptors are involved in mediating the effect of inactivated avian influenza virus H5N1 on IL-6 & CXCL8 mRNA expression in respiratory epithelium. PLoS ONE, 2017, 12, e0176974.	1.1	9
89	ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen. OncoTargets and Therapy, 2016, 9, 2121.	1.0	17
90	CYP2D6 polymorphisms and their influence on risperidone treatment. Pharmacogenomics and Personalized Medicine, 2016, Volume 9, 131-147.	0.4	26

#	ARTICLE	IF	CITATIONS
91	Exome Sequencing Identifies Compound Heterozygous Mutations in SCN5A Associated with Congenital Complete Heart Block in the Thai Population. <i>Disease Markers</i> , 2016, 2016, 1-10.	0.6	10
92	Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study. <i>PLoS ONE</i> , 2016, 11, e0157531.	1.1	8
93	HLA-B*58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand. <i>Frontiers in Pharmacology</i> , 2016, 7, 186.	1.6	54
94	Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients. <i>Frontiers in Pharmacology</i> , 2016, 7, 475.	1.6	17
95	Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 843.	1.0	11
96	Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 141-146.	0.7	35
97	Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 225-234.	0.7	94
98	9-Hydroxyrisperidone-Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 119, 267-272.	1.2	22
99	A success story in pharmacogenomics: genetic ID card for SJS/TEN. <i>Pharmacogenomics</i> , 2016, 17, 455-458.	0.6	28
100	High Efficacy of Primaquine Treatment for Plasmodium vivax in Western Thailand. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 1086-1089.	0.6	13
101	Development and Validation of Liquid Chromatography/Tandem Mass Spectrometry Analysis for Therapeutic Drug Monitoring of Risperidone and 9-Hydroxyrisperidone in Pediatric Patients with Autism Spectrum Disorders. <i>Journal of Clinical Laboratory Analysis</i> , 2016, 30, 1236-1246.	0.9	17
102	A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis. <i>Drug Metabolism and Pharmacokinetics</i> , 2016, 31, 117-122.	1.1	26
103	Development of Pyrosequencing Method for Detection of UGT1A1 Polymorphisms in Thai Colorectal Cancers. <i>Journal of Clinical Laboratory Analysis</i> , 2016, 30, 84-89.	0.9	16
104	Correlation of UGT1A1 *28 and *6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients. <i>Drug Metabolism and Pharmacokinetics</i> , 2016, 31, 90-94.	1.1	28
105	Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels. <i>Drug Metabolism and Pharmacokinetics</i> , 2016, 31, 156-162.	1.1	31
106	Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 277-283.	0.8	22
107	Hyperuricemia in Children and Adolescents with Autism Spectrum Disorder Treated with Risperidone: The Risk Factors for Metabolic Adverse Effects. <i>Frontiers in Pharmacology</i> , 2016, 7, 527.	1.6	20
108	Comparison of a New In-House and Three Published HLA-B*15:02 Screening Methods for Prevention of Carbamazepine-Induced Severe Drug Reactions. <i>PLoS ONE</i> , 2016, 11, e0155907.	1.1	7

#	ARTICLE	IF	CITATIONS
109	Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 191.	1.0	16
110	Polymorphisms of the ApoE (Apolipoprotein E) Gene and Their Influence on Dyslipidemia in HIV-1-Infected Individuals. <i>Japanese Journal of Infectious Diseases</i> , 2015, 68, 5-12.	0.5	10
111	A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study. <i>Pharmacogenomics and Personalized Medicine</i> , 2015, 8, 155.	0.4	3
112	The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand. <i>Pharmacogenomics and Personalized Medicine</i> , 2015, 8, 163.	0.4	5
113	Pharmacokinetics of mitragynine in man. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2421.	2.0	62
114	Significant Association of HLA-B Alleles and Genotypes in Thai Children with Autism Spectrum Disorders: A Case-Control Study. <i>Disease Markers</i> , 2015, 2015, 1-7.	0.6	18
115	Pharmacogenetics and Clinical Biomarkers for Subtherapeutic Plasma Efavirenz Concentration in HIV-1 Infected Thai Adults. <i>Drug Metabolism and Pharmacokinetics</i> , 2014, 29, 289-295.	1.1	18
116	ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2195-2201.	1.3	28
117	HLA-B*58:01 allele is strongly associated with allopurinol-induced severe cutaneous adverse reactions in a Thai population. <i>Clinical and Translational Allergy</i> , 2014, 4, P120.	1.4	2
118	HLA-B*15:02 genotype associated with hypersensitivity syndrome to lamotrigine in Thai population. <i>Clinical and Translational Allergy</i> , 2014, 4, P121.	1.4	1
119	Evaluation of a pharmacogenetic test in Thailand for abacavir hypersensitivity screening in human immunodeficiency virus infection. <i>Clinical and Translational Allergy</i> , 2014, 4, P122.	1.4	0
120	Association between HLA-B*1502 allele and aromatic antiepileptic drugs-induced hypersensitivity syndrome reactions and the HLA-B*15:02 pharmacogenetics screening in autistic spectrum disorder. <i>Clinical and Translational Allergy</i> , 2014, 4, P124.	1.4	2
121	CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 292-296.	1.1	18
122	HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity. <i>Frontiers in Genetics</i> , 2014, 5, 478.	1.1	31
123	Pharmacogenomics of drug-induced hypersensitivity reactions: challenges, opportunities and clinical implementation. <i>Asian Pacific Journal of Allergy and Immunology</i> , 2014, 32, 111-23.	0.2	16
124	Impact of Pharmacogenetic Markers of CYP2B6, Clinical Factors, and Drug-Drug Interaction on Efavirenz Concentrations in HIV/Tuberculosis-Coinfected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1019-1024.	1.4	37
125	Small-Dense LDL Cholesterol/Large-Buoyant LDL Cholesterol Ratio as an Excellent Marker for Indicating Lipodystrophy in HIV-Infected Patients. <i>American Journal of Clinical Pathology</i> , 2013, 140, 506-515.	0.4	7
126	High Plasma Efavirenz Concentration and CYP2B6 Polymorphisms in Thai HIV-1 Infections. <i>Drug Metabolism and Pharmacokinetics</i> , 2013, 28, 391-397.	1.1	20



#	ARTICLE	IF	CITATIONS
127	Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 6, 93.	0.4	21
128	Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 6, 37.	0.4	23
129	CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 6, 85.	0.4	28
130	Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand. <i>Journal of the International AIDS Society</i> , 2012, 15, 12-12.	1.2	28
131	Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 1005-1012.	1.1	34
132	Impact of CYP2D6 Polymorphisms on Tamoxifen Responses of Women with Breast Cancer: A Microarray-based Study in Thailand. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 4549-4553.	0.5	35
133	Molecular epidemiology of human papillomavirus genotype in women with high-grade squamous intraepithelial lesion and cervical cancer: Will a quadrivalent vaccine be necessary in Thailand?. <i>Journal of Medical Virology</i> , 2011, 83, 119-126.	2.5	9
134	The Application of Artificial Neural Networks for Phenotypic Drug Resistance Prediction: Evaluation and Comparison with Other Interpretation Systems. <i>Japanese Journal of Infectious Diseases</i> , 2010, 63, 87-94.	0.5	26
135	Genotypic resistance mutations in treatment-naïve and treatment-experienced patients under widespread use of antiretroviral drugs in Thailand: implications for further epidemiologic surveillance. <i>Japanese Journal of Infectious Diseases</i> , 2007, 60, 284-9.	0.5	16
136	Pharmaco-genomics of antiretroviral drugs. , 0, , 297-312.		0
137	Implementation of HLA-B*15:02 Genotyping as Standard-of-Care for Reducing Carbamazepine/Oxcarbazepine Induced Cutaneous Adverse Drug Reactions in Thailand. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
138	Economic Evaluation of Multiple-Pharmacogenes Testing for the Prevention of Adverse Drug Reactions in People Living with HIV. <i>ClinicoEconomics and Outcomes Research</i> , 0, Volume 14, 447-463.	0.7	3